Pure Global AI
NCT06380153Not yet recruiting

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral Administration
Ganzhou Hemay Pharmaceutical Co., LtdPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
Hemay005
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Dec 01, 2024
Enrollment
24 participants
Primary outcome

Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax）,Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t）,Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf),Relevant pharmacokinetic parameters，half-life (T1/2),Relevant pharmacokinetic parameters，clearance (CL/F),Relevant pharmacokinetic parameters，volume of distribution (Vz/F),Relevant pharmacokinetic parameters ，Renal clearance rate（CLr）

Summary

The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects
 with mild to moderate renal impairment and normal renal function, and to provide a basis for
 the formulation of clinical medication regimens for patients with renal impairment.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06380153
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06380153 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.